Antipsychotic combinations for schizophrenia.

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Trials

Background:

• Many individuals with schizophrenia exhibit inadequate responses to initial antipsychotic treatments.
• Antipsychotic drug combinations are sometimes employed when monotherapy proves insufficient.

Purpose of the Study:

• To evaluate the effectiveness of antipsychotic combination therapy for schizophrenia.
• To assess the safety profile of antipsychotic combination therapy in schizophrenia patients.

Main Methods:

• Systematic review and meta-analysis of randomized and quasi-randomized controlled trials.
• Searched multiple databases including PubMed, MEDLINE, PsycINFO, CINAHL, BIOSIS, AMED, and clinical trial registries.
• Included 62 studies comparing antipsychotic combinations with monotherapy, with 31 focusing on clozapine combinations.

Main Results:

• Very low-quality evidence suggests combination therapy may improve clinical response (RR 0.73, 95% CI 0.63 to 0.85), primarily driven by clozapine studies.
• No significant differences were found in preventing relapse (RR 0.63, 95% CI 0.31 to 1.29), early treatment discontinuation (RR 0.89, 95% CI 0.73 to 1.07), or hospitalizations (RR 0.96, 95% CI 0.36 to 2.55).
• No evidence of increased serious adverse events was observed (RR 1.05, 95% CI 0.65 to 1.69), with limited data on quality of life.

Conclusions:

• Current evidence, largely from short-term trials, indicates very low-quality support for improved clinical response with antipsychotic combinations.
• Low-quality evidence suggests no significant difference in preventing early discontinuation, relapse, or serious adverse events compared to monotherapy.
• Further research is needed to establish long-term efficacy and safety of antipsychotic combination treatments for schizophrenia.